Valuation: Guided Therapeutics, Inc.

Market Cap 2.39Cr 2.1Cr 1.98Cr 1.81Cr 3.38Cr 229.46Cr 3.41Cr 24Cr 9.2Cr 117.23Cr 8.99Cr 8.79Cr 376.76Cr P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 2.68Cr 2.35Cr 2.22Cr 2.03Cr 3.79Cr 257.03Cr 3.82Cr 27Cr 10Cr 131.31Cr 10Cr 9.85Cr 422.02Cr EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
09/09 Guided Therapeutics, Inc. and Türkiye Ministry of Health Reach Collaborative Agreement for Primary Screening Test for Cervical Cancer CI
13/08 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
15/07 Guided Therapeutics, Inc. Announces New Agreement With Yuanshuo Medical Instruments Corporation CI
16/06 Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA CI
15/05 Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
31/03 Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
31/03 Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
18/12 Guided Therapeutics, Inc. Announces Preliminary Findings from Its FDA Pivotal Clinical Trial CI
11/12 Guided Therapeutics, Inc. Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor CI
19/11 Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation CI
14/11 Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
19/25/19 Guided Therapeutics, Inc. Receives $70,000 from New Chinese Distribution Partner That Provides Products for 2 Million Annual Cervical Cancer Screenings CI
15/25/15 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day+1.22%
1 week+7.83%
Current month+10.22%
1 month-0.80%
3 months-4.62%
6 months+24.00%
Current year-54.07%
1 week 0.18
Extreme 0.1819
0.25
1 month 0.18
Extreme 0.1818
0.25
Current year 0.17
Extreme 0.17
0.54
1 year 0.15
Extreme 0.15
0.54
3 years 0.06
Extreme 0.064
0.54
5 years 0.06
Extreme 0.062
0.78
10 years 0.02
Extreme 0.0206
3,200
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 70 01/12/2016
Director/Board Member 76 10/04/2006
Chairman 67 01/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
10/03/26 Free

Chairman

1,10,000 0.1316%
10/03/26 Others

Director

4,66,991 0.5586%
10/03/26 Free

Director

1,10,000 0.1316%
Change 5-day change 1-year change 3-year change Capi.($)
+1.22%+7.83%-2.75%+77.14% 2.39Cr
-0.50%+3.62%+46.99%+33.49% 25TCr
+0.32%+5.99%+23.71%-10.93% 16TCr
+1.42%+3.01%-7.52%+38.17% 14TCr
-1.70%+1.34%-55.25%-18.36% 6.37TCr
+0.65%-2.23%+14.64%+24.23% 4.97TCr
-0.03%+10.43%+41.76%+54.36% 4.87TCr
+1.56%+0.05%-15.70%-20.02% 4.79TCr
+0.75%+2.82%+50.64%+60.00% 4.26TCr
-1.42%+12.68%+192.87%+105.46% 4.08TCr
Average +0.23%+4.58%+28.94%+34.35% 8.44TCr
Weighted average by Cap. +0.12%+4.19%+27.14%+24.50%

Financials

2024 2025
Net sales 7T 6.14T 5.8T 5.29T 9.9T 7L 9.97T 69.42T 26.89T 3L 26.28T 25.71T 11.02L 8L 7L 6L 6L 10.84L 7.35Cr 10.92L 76.07L 29.46L 3.76Cr 28.8L 28.17L 12Cr
Net income -24.17L -21.21L -20.03L -18.25L -34.17L -23Cr -34.42L -2.4Cr -92.84L -12Cr -90.75L -88.79L -38Cr -31.96L -28.04L -26.49L -24.14L -45.19L -31Cr -45.51L -3.17Cr -1.23Cr -16Cr -1.2Cr -1.17Cr -50Cr
Net Debt 17.71L 15.54L 14.68L 13.38L 25.04L 17Cr 25.22L 1.76Cr 68.03L 8.67Cr 66.49L 65.06L 28Cr 28.76L 25.24L 23.84L 21.72L 40.66L 28Cr 40.95L 2.85Cr 1.1Cr 14Cr 1.08Cr 1.06Cr 45Cr
Logo Guided Therapeutics, Inc.
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
3
Date Price Change Volume
25/26/25 $0.2480 +1.22% 21,149
23/26/23 $0.2450 +11.36% 2,650
22/26/22 $0.2200 -0.22% 1,501
21/26/21 $0.2205 -4.14% 2,323
  1. Stock Market
  2. Stocks
  3. GTHP Stock